Assessing Adherence to Antihypertensive Therapy in Primary Health Care in Namibia: Findings and Implications

Abstract

IntroductionNamibia has the highest burden and incidence of hypertension in sub-Sahara Africa. Though non-adherence to antihypertensive therapy is an important cardiovascular risk factor, little is known about potential ways to improve adherence in Namibia following universal access. The objective of this study is to validate the Hill-Bone compliance scale and determine the level and predictors of adherence to antihypertensive treatment in primary health care settings in sub-urban townships of Windhoek, Namibia.MethodsReliability was determined by Cronbach’s alpha. Principal component analysis (PCA) was used to assess construct validity.ResultsThe PCA was consistent with the three constructs for 12 items, explaining 24.1, 16.7 and 10.8% of the variance. Cronbach’s alpha was 0.695. None of the 120 patients had perfect adherence to antihypertensive therapy, and less than half had acceptable levels of adherence (≥ 80%). The mean adherence level was 76.7 ± 8.1%. Three quarters of patients ever missed their scheduled clinic appointment. Having a family support system (OR = 5.4, 95% CI 1.687–27.6, p = 0.045) and attendance of follow-up visits (OR = 3.1, 95% CI 1.1–8.7, p = 0.03) were significant predictors of adherence. Having HIV/AIDs did not lower adherence.ConclusionsThe modified Namibian version of the Hill-Bone scale is reliable and valid for assessing adherence to antihypertensives in Namibia. There is sub-optimal adherence to antihypertensive therapy among primary health cares in Namibia. This needs standardized systems to strengthen adherence monitoring as well as investigation of other factors including transport to take full advantage of universal access.

Ongoing strategies to improve the management of upper respiratory tract infections and reduce inappropriate antibiotic use particularly among lower and middle-income countries: findings and implications for the future

“…This is again very different to high income countries where typically expenditure on pharmaceuticals is 15% or less of total healthcare expenditure and there is often universal healthcare 176,177 . There can also be long waiting times to see physicians in primary healthcare centres (PHCs) in LMICs, as well as long distances to travel to PHCs, putting time pressures on physicians as well as patients to seek alternative approaches including community pharmacists and private physicians 49,69,98,[178][179][180][181][182] .…”

Knowledge regarding medicines management of type 2 diabetes amongst patients attending a Community Health Centre in South Africa

“…[50][51][52][53][54][55] Such activities though must take account of the fact that the patient population attending CHCs in South Africa (Table 1) typically have no formal education or only primary education, similar to other ambulatory care settings in South Africa and other African countries. [9,20,24,[56][57][58] Consequently, storytelling and other similar approaches may be appropriate, alongside initiatives such as diaries, pictograms and counselling involving pharmacists, to improve patient knowledge and subsequent medicine use. [59][60][61] However, we are aware that socio-demographic and cultural barriers including issues of exercise, diet and self-monitoring of blood glucose levels, have restricted self-care activities in developing countries.…”

Statin use in Brazil: findings and implications

“…In view of the rising prevalence of NCDs, and their impact on morbidity and mortality, the Pan American Health Organization (PAHO) drew up a Plan of Action for 2013 to 2019. The objective is to prevent and control NCDs in view of their growing burden [6], which is in line with the Sustainable Development Goal for NCDs proposed by the World Health Organisation (WHO) [5,7] Universal health coverage, including access to essential medicines, people-centred primary health care and social protection mechanisms are important tools to support prevention and control of NCDs [8,9]. Patient co-payment is a particular issue affecting adherence to medicines negatively impacting on morbidity and mortality [10][11][12].…”